Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.

@article{Schievink2015SurrogateEI,
  title={Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.},
  author={Bauke Schievink and Peter G. M. Mol and Hiddo Jan Lambers Heerspink},
  journal={Current opinion in nephrology and hypertension},
  year={2015},
  volume={24 6},
  pages={
          492-7
        }
}
PURPOSE OF REVIEW There is increased interest in developing surrogate endpoints for clinical trials of chronic kidney disease progression, as the established clinically meaningful endpoint end-stage renal disease requires large and lengthy trials to assess drug efficacy. We describe recent developments in the search for novel surrogate endpoints. RECENT FINDINGS Declines in estimated glomerular filtration rate (eGFR) of 30% or 40% and albuminuria have been proposed as surrogates for end-stage… CONTINUE READING
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease ( PLANET I ) : a randomised clinical trial

D deZeeuw, DA Anzalone, VA Cain
  • Lancet Diabetes Endocrinol
  • 2015

A novel approach for establishing cardiovascular drug efficacy

PA Smink, Y Miao, Eijkemans MJC
  • Nat Rev Drug Discov
  • 2014